LIST OF TABLES
• TABLE 1 KEY HUMAN INSULIN DRUGS : YEAR OF PATENT EXPIRY ................................................................................ 38
• TABLE 2
KEY HUMAN INSULIN THERAPIES UNDER PIPELINE DEVELOPMENT & COMMERCIALIZATION : 2005-2015 ............................................................................................................... 50
• TABLE 3 HUMAN INSULIN PIPELINE : MAJOR COMPANIES INVOLVED .......................................................................... 51
• TABLE 4 HUMAN INSULIN PIPELINE : STAGES OF CLINICAL TRIAL ............................................................................... 52
• TABLE 5 GLOBAL HUMAN INSULIN MARKET SIZE , BY PRODUCT TYPE , 2013 – 2020 ( USD MILLION )............................................................................................................................... 57
• TABLE 6 HUMAN INSULIN DRUGS MARKET SIZE , BY REGION , 2013 – 2020 ( USD MILLION )........................................ 59
• TABLE 7 HUMAN INSULIN DELIVERY DEVICES MARKET SIZE , BY REGION , 2013 – 2020 ( USD MILLION )............................................................................................................................... 60
• TABLE 8 GLOBAL HUMAN INSULIN DRUGS MARKET SIZE , BY TYPE , 2013 – 2020 ( USD MILLION )............................................................................................................................... 62
• TABLE 9 GLOBAL INSULIN ANALOGS AND BIOSIMILARS MARKET SIZE , BY TYPE , 2013 – 2020 ( USD MILLION )............................................................................................................................... 63
• TABLE 10 INSULIN ANALOGS AND BIOSIMILARS MARKET SIZE , BY REGION , 2013 – 2020 ( USD MILLION )................... 64
• TABLE 11 LONG-ACTING INSULIN ANALOGS AND BIOSIMILARS MARKET SIZE , BY REGION , 2013 – 2020 ( USD MILLION ).......................................................................................................... 65
• TABLE 12 RAPID-ACTING INSULIN ANALOGS AND BIOSIMILARS MARKET SIZE , BY REGION , 2013 – 2020 ( USD MILLION ).......................................................................................................... 66
• TABLE 13 PREMIXED INSULIN ANALOGS AND BIOSIMILARS MARKET SIZE , BY REGION , 2013 – 2020 ( USD MILLION ).......................................................................................................... 67
• TABLE 14 GLOBAL HUMAN INSULIN BIOLOGICS MARKET SIZE , BY TYPE , 2013 – 2020 ( USD MILLION )........................ 68
• TABLE 15 HUMAN INSULIN BIOLOGICS MARKET SIZE , BY REGION , 2013 – 2020 ( USD MILLION ).................................. 69
• TABLE 16 SHORT-ACTING HUMAN INSULIN BIOLOGICS MARKET SIZE , BY REGION , 2013 – 2020 ( USD MILLION ).......................................................................................................... 70
• TABLE 17 INTERMEDIATE-ACTING HUMAN INSULIN BIOLOGICS MARKET SIZE , BY REGION , 2013 – 2020 ( USD MILLION ).......................................................................................................... 71
• TABLE 18 PREMIXED HUMAN INSULIN BIOLOGICS MARKET SIZE , BY REGION , 2013 – 2020 ( USD MILLION )............... 72
• TABLE 19 GLOBAL HUMAN INSULIN DRUGS MARKET SIZE , BY PRODUCT TYPE , 2013 – 2020 ( USD MILLION )............................................................................................. 74
• TABLE 20 GLOBAL INSULIN ANALOGS AND BIOSIMILARS MARKET SIZE , BY BRAND , 2013 – 2020 ( USD MILLION )........................................................................................................... 75
• TABLE 21 INSULIN ANALOGS AND BIOSIMILARS MARKET SIZE , BY REGION , 2013 – 2020 ( USD MILLION )................... 76
sales @ marketsandmarkets . com www . marketsandmarkets . com
18